Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesEndocrinologyCVS Caremark Insulin Pump Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCVS CaremarkPolicy 3762-C

    Initial Prior Authorization with Quantity — Disposable Insulin Pumps

    Customize your policy alerts

    Sign up for cvs_caremark Policy 3762-C alerts

    Get alerted when Policy 3762-C changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs initial prior authorization and quantity limits for pharmacy-dispensed disposable insulin pumps, including Omnipod, Twiist, and V-Go products, for patients with diabetes.

    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity — Disposable Insulin Pumps
    Policy CodePolicy 3762-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument glucose self-testing frequency or current continuous glucose monitor use; most pump requests require an average of at least 4 glucose tests per day.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Product families referenced
    12 monthsApproval duration
    4/dayGlucose testing for most pump requests
    10/25 daysOmnipod GO quantity limit
    200 units/72 hours

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Omnipod increased-quantity threshold
    300 units/72 hoursTwiist increased-quantity threshold

    Eligibility and Product-Specific Criteria

    Omnipod, Twiist, and V-Go Therapy Criteria

    Authorization may be granted for the requested medical device when the request is for other Omnipod products (e.g., Omnipod DASH or Omnipod 5), Twiist, or V-Go and the applicable therapy-status criteria are met.

    ONE of the following therapy-status pathways

    • Patient is NOT currently established on therapy with an insulin pump

      • The patient is managing their diabetes with multiple daily insulin injections.
      • The patient has completed a comprehensive diabetes education program.
      • The patient has documented frequency of glucose self-testing an average of at least 4 times per day OR the patient is using a continuous glucose monitor (CGM).
      • If the patient does NOT have a diagnosis of type 1 diabetes, ONE of the following must also be met

        • The patient has experienced an elevated glycosylated hemoglobin level (e.g., HbA1c greater than 7 percent) while on multiple daily injections of insulin (i.e., at least 3 injections per day) for at least 6 months.
        • While on multiple daily injections of insulin (i.e., at least 3 injections per day) for at least 3 months, the patient has experienced a history of recurrent hypoglycemia (e.g., blood glucose levels less than 70 mg/dL), wide fluctuations in blood glucose before mealtime, a 'dawn' phenomenon with fasting blood sugars frequently exceeding 200 mg/dL, or a history of severe glycemic excursions.
    • Patient is currently established on therapy with an insulin pump

      • The patient has documented frequency of glucose self-testing an average of at least 4 times per day OR the patient is using a continuous glucose monitor (CGM).

    Product-Specific Starter-Kit and Quantity Criteria

    The applicable product-specific starter-kit or quantity criterion must be met in addition to the therapy criteria when the corresponding product or quantity is requested.

    Applicable product-specific condition

    • If an Omnipod starter kit is being requested, the patient has not received an Omnipod starter kit within the past 4 years.
    • If a Twiist starter kit is being requested, the patient has not received a Twiist starter kit within the past 3 years.
    • If additional quantities of Omnipod pods are being requested, the patient requires more than 200 units of insulin within a 72-hour period.> 200 units of insulin per 72 hours
    • If additional quantities of Twiist Refill Kits or Refill Kits with Infusion Sets are being requested, the patient requires more than 300 units of insulin within a 72-hour period.> 300 units of insulin per 72 hours

    Omnipod GO for Type 2 Diabetes Mellitus

    Authorization may be granted for the requested medical device when the patient has a diagnosis of type 2 diabetes mellitus, the request is for Omnipod GO, and all of the following criteria are met.

    ALL of the following

    • The patient does NOT require bolus or mealtime insulin.
    • The patient has completed a comprehensive diabetes education program.
    • ONE of the following glucose-monitoring criteria is met

      • The patient has documented frequency of glucose self-testing at least once daily.
      • The patient has been using a continuous glucose monitor (CGM).

    Clinical Thresholds and Quantity Parameters

    Glucose self-testing for most pump requests
    Applicable requestsMost disposable insulin pump requests, including initial and established pump therapy pathways
    Minimum testing frequencyGlucose self-testing averaging at least 4 times per day
    AlternativeCurrent use of a continuous glucose monitor (CGM) also meets the monitoring criterion
    Glucose self-testing for Omnipod GO type 2 requests
    Applicable productOmnipod GO for patients with type 2 diabetes mellitus
    Required testing frequencyDocumented glucose self-testing at least once daily
    Alternative

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Omnipod, Twiist, and V-Go Prior Authorization

    Prior authorization is required for other Omnipod products (including Omnipod DASH and Omnipod 5), Twiist, or V-Go. The applicable initial authorization pathway depends on whether the patient is already established on insulin-pump therapy and requires the documentation described below.

    • Requests for other Omnipod products, Twiist, or V-Go may be authorized when the applicable initial-therapy or established-pump criteria are met.
    Prior Authorization

    Omnipod GO for Type 2 Diabetes

    For patients with type 2 diabetes mellitus, Omnipod GO requires a separate authorization pathway. The patient must not require bolus or mealtime insulin, must complete comprehensive diabetes education, and must meet one of the specified glucose-monitoring or basal-insulin hypersensitivity criteria.

    • The request must be for Omnipod GO.
    • The patient must have a diagnosis of type 2 diabetes mellitus.

    Policy Context

    Disposable insulin pumps are pharmacy-dispensed devices used to support insulin delivery in diabetes management. The policy distinguishes requests for patients initiating pump therapy from those already established on an insulin pump. For most Omnipod, Twiist, and V-Go requests, eligibility is tied to the patient’s treatment status, diabetes education, and documented glucose monitoring. The policy also includes a separate Omnipod GO pathway for type 2 diabetes when the patient does not require bolus or mealtime insulin and meets the specified monitoring or basal-insulin hypersensitivity criteria.

    Fill-Period Calculation

    Fill-period calculation
    30-day fill periodA 25-day duration is used
    90-day fill periodA 75-day duration is used
    PurposeThe shortened durations allow time for refill processing
    Policy Summary
    PayerCVS Caremark
    PolicyInitial Prior Authorization with Quantity — Disposable Insulin Pumps
    Policy CodePolicy 3762-C
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionDocument glucose self-testing frequency or current continuous glucose monitor use; most pump requests require an average of at least 4 glucose tests per day.
    SourceLink
    On This Page
    Eligibility and Product-Specific CriteriaClinical Thresholds and Quantity ParametersPrior Authorization and Documentation RequirementsPolicy ContextFill-Period Calculation
    The patient has a hypersensitivity to an ingredient in ALL available basal insulin (e.g., long-acting insulin or intermediate-acting insulin).
    Current use of a continuous glucose monitor (CGM) may be used instead of daily self-testing
    Elevated HbA1c
    Applicable populationPatients without a diagnosis of type 1 diabetes
    HbA1c thresholdGreater than 7 percent
    Treatment contextElevated HbA1c must occur while receiving at least 3 insulin injections per day for at least 6 months
    Insulin regimen for non-type 1 glycemic need
    Injection frequencyAt least 3 insulin injections per day
    Elevated HbA1c pathwayThe regimen must be maintained for at least 6 months when documenting elevated HbA1c
    Qualifying glycemic-problem pathwayThe regimen must be maintained for at least 3 months when documenting recurrent hypoglycemia, wide premeal fluctuations, dawn phenomenon, or severe glycemic excursions
    Omnipod additional-quantity threshold
    Applicable productAdditional quantities of Omnipod pods
    Insulin-use thresholdMore than 200 units of insulin within a 72-hour period
    Higher quantity limit15 pods per 25 days or 45 pods per 75 days when insulin use exceeds 200 units per 72-hour period
    Twiist additional-quantity threshold
    Applicable productAdditional Twiist Refill Kits or Refill Kits with Infusion Sets
    Insulin-use thresholdMore than 300 units of insulin within a 72-hour period
    Higher quantity limitTwo refill kits per 25 days or six refill kits per 75 days when insulin use exceeds 300 units per 72-hour period
    Hypoglycemia example
    Qualifying glycemic problemHistory of recurrent hypoglycemia
    Blood glucose exampleBlood glucose levels less than 70 mg/dL
    Treatment contextThe problem must occur while receiving at least 3 insulin injections per day for at least 3 months
    Dawn phenomenon example
    Qualifying glycemic problemDawn phenomenon
    Fasting blood sugar exampleFasting blood sugars frequently exceeding 200 mg/dL
    Treatment contextThe problem must occur while receiving at least 3 insulin injections per day for at least 3 months
    Billing Rule

    Quantity Limits Apply

    Quantity limits apply by product, fill period, starter-kit history, and insulin-use level. The 25-day limits apply to a 30-day fill period, and the 75-day limits apply to a 90-day fill period to allow time for refill processing.

    • Omnipod GO: 10 pods per 25 days or 30 pods per 75 days.
    • Other Omnipod products: starter kit, 1 kit per 999 days; pod refills, 10 pods per 25 days or 30 pods per 75 days when insulin use is 200 units or less per 72 hours; 15 pods per 25 days or 45 pods per 75 days when insulin use exceeds 200 units per 72 hours.
    • Twiist: starter kit, 1 kit per 999 days.
    • Twiist Refill Kit: 1 kit (10 cassettes) per 25 days or 3 kits (30 cassettes) per 75 days when insulin use is 300 units or less per 72 hours; 2 kits (20 cassettes) per 25 days or 6 kits (60 cassettes) per 75 days when insulin use exceeds 300 units per 72 hours.
    • Twiist Refill Kit with Infusion Sets: 1 kit (10 cassettes and 10 infusion sets) per 25 days or 3 kits (30 cassettes and 30 infusion sets) per 75 days when insulin use is 300 units or less per 72 hours; 2 kits (20 cassettes and 20 infusion sets) per 25 days or 6 kits (60 cassettes and 60 infusion sets) per 75 days when insulin use exceeds 300 units per 72 hours.
    • V-Go: 30 pumps per 25 days or 90 pumps per 75 days.
    Note

    Authorization Duration

    The authorization duration is 12 months under policy code 3762-C.

    • Duration of approval: 12 months.

    Unsupported block type: documentation

    Documentation Required

    Diabetes Education Documentation

    Document completion of a comprehensive diabetes education program when required by the applicable pathway.

    • Required for patients not currently established on pump therapy who are requesting other Omnipod products, Twiist, or V-Go.
    • Required for patients with type 2 diabetes requesting Omnipod GO.
    Documentation Required

    Glucose Monitoring Documentation

    Submit glucose-monitoring documentation for the applicable pathway. For other Omnipod products, Twiist, and V-Go, document self-testing an average of at least 4 times per day or current CGM use; for Omnipod GO in type 2 diabetes, document self-testing at least once daily or CGM use.

    • Initial or established-pump pathway: glucose self-testing average of at least 4 times daily OR use of a continuous glucose monitor (CGM).
    • Omnipod GO type 2 pathway: glucose self-testing at least once daily OR use of a CGM.
    Documentation Required

    Non-Type 1 Diabetes Clinical Need

    For a patient without type 1 diabetes, document the required evidence of inadequate glycemic control or clinically significant glycemic instability while receiving multiple daily insulin injections.

    • Elevated HbA1c, such as greater than 7 percent, while receiving at least 3 insulin injections per day for at least 6 months; OR
    • While receiving at least 3 insulin injections per day for at least 3 months, a history of recurrent hypoglycemia (for example, glucose below 70 mg/dL), wide premeal glucose fluctuations, dawn phenomenon with fasting glucose frequently above 200 mg/dL, or severe glycemic excursions.
    Documentation Required

    Justify Additional Quantities

    Additional quantities require documentation of the patient’s insulin requirements during a 72-hour period. The applicable threshold depends on the requested product.

    • Additional Omnipod pods: more than 200 units of insulin within 72 hours.
    • Additional Twiist Refill Kits or Refill Kits with Infusion Sets: more than 300 units of insulin within 72 hours.
    Documentation Required

    Omnipod GO Type 2 Documentation

    For Omnipod GO in type 2 diabetes, document that the patient does not require bolus or mealtime insulin and document the applicable clinical factor supporting authorization.

    • The patient must have completed a comprehensive diabetes education program.
    • The patient must document glucose self-testing at least once daily OR use of a CGM; OR document hypersensitivity to an ingredient in all available basal insulin, such as long-acting or intermediate-acting insulin.
    Denial Risk

    Missing Initial Pump-Therapy Prerequisites

    Requests may be denied when initial pump-therapy prerequisites are not documented. A patient not currently established on insulin-pump therapy must be managing diabetes with multiple daily insulin injections and must have completed comprehensive diabetes education, in addition to meeting the glucose-monitoring requirement.

    • Document multiple daily insulin injections.
    • Document completion of comprehensive diabetes education.
    • Document glucose self-testing averaging at least 4 times daily or CGM use.
    Denial Risk

    Insufficient Glycemic-Need Documentation

    For patients without type 1 diabetes, authorization may be denied when the record does not establish the required glycemic need while on multiple daily injections.

    • Missing HbA1c elevation greater than 7 percent after at least 6 months of at least 3 injections daily; or
    • Missing documentation of a qualifying recurrent hypoglycemia, premeal glucose fluctuation, dawn phenomenon, or severe glycemic-excursion history after at least 3 months of at least 3 injections daily.
    Denial Risk

    Quantity Threshold Not Met

    Additional Omnipod or Twiist quantities may be denied when the patient’s documented insulin use does not exceed the applicable 72-hour threshold.

    • Omnipod: additional pod quantities require more than 200 units of insulin within 72 hours.
    • Twiist: additional Refill Kit or Refill Kit with Infusion Sets quantities require more than 300 units of insulin within 72 hours.
    Denial Risk

    Recent Starter Kit

    A starter-kit request may be denied when the patient recently received a starter kit from the same manufacturer.

    • Omnipod starter kit: the patient must not have received an Omnipod starter kit within the past 4 years.
    • Twiist starter kit: the patient must not have received a Twiist starter kit within the past 3 years.
    Denial Risk

    Omnipod GO Criteria Not Met

    Omnipod GO authorization may be denied when the type 2 diabetes criteria are incomplete, including failure to document the required insulin regimen, diabetes education, or qualifying glucose-monitoring or basal-insulin hypersensitivity criterion.

    • The patient must not require bolus or mealtime insulin.
    • The patient must have completed comprehensive diabetes education.
    • The patient must document self-testing at least once daily or CGM use, or hypersensitivity to an ingredient in all available basal insulin.